ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.45
-0.22 (-2.54%)
At close: Mar 9, 2026, 4:00 PM EDT
8.33
-0.12 (-1.42%)
After-hours: Mar 9, 2026, 7:58 PM EDT
ImmunityBio Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Cash & Equivalents | 88.33 | 143.43 | 265.45 | 104.64 | 181.1 | Upgrade
|
| Short-Term Investments | 154.48 | 6.38 | 1.01 | 2.54 | 136.02 | Upgrade
|
| Cash & Short-Term Investments | 242.82 | 149.81 | 266.46 | 107.18 | 317.12 | Upgrade
|
| Cash Growth | 62.09% | -43.78% | 148.60% | -66.20% | 230.12% | Upgrade
|
| Accounts Receivable | 42.57 | 2.36 | - | - | - | Upgrade
|
| Other Receivables | 0.05 | 0.29 | 3.17 | 1.89 | 1.33 | Upgrade
|
| Receivables | 42.62 | 2.65 | 3.17 | 1.89 | 1.33 | Upgrade
|
| Inventory | 0.91 | 8.27 | - | 2.16 | - | Upgrade
|
| Prepaid Expenses | 16.85 | 16.73 | 13.98 | 14.74 | 12.25 | Upgrade
|
| Other Current Assets | 11.68 | 7.12 | 10.47 | 14.6 | 3.65 | Upgrade
|
| Total Current Assets | 314.88 | 184.59 | 294.08 | 140.58 | 334.35 | Upgrade
|
| Property, Plant & Equipment | 147.55 | 170.46 | 182.68 | 189.58 | 119.17 | Upgrade
|
| Long-Term Investments | 14.21 | 0.7 | 0.89 | 0.84 | 7.6 | Upgrade
|
| Goodwill | 0.91 | 0.91 | - | - | - | Upgrade
|
| Other Intangible Assets | 13.04 | 15.02 | 17.09 | 20 | 1.42 | Upgrade
|
| Other Long-Term Assets | 3.94 | 4.13 | 2.82 | 4.73 | - | Upgrade
|
| Total Assets | 501.9 | 382.93 | 504.45 | 362.36 | 468.91 | Upgrade
|
| Accounts Payable | 6.98 | 6.73 | 9.2 | 21.02 | 11.42 | Upgrade
|
| Accrued Expenses | 42.01 | 38.28 | 39.53 | 34.23 | 33.94 | Upgrade
|
| Short-Term Debt | 1.75 | 1.25 | 1.48 | 433.32 | 301.83 | Upgrade
|
| Current Portion of Leases | 7.59 | 7.47 | 5.31 | 2.73 | 3.01 | Upgrade
|
| Other Current Liabilities | 3.42 | 1.22 | 2.77 | 9.57 | 18.8 | Upgrade
|
| Total Current Liabilities | 61.75 | 54.94 | 58.28 | 500.86 | 369 | Upgrade
|
| Long-Term Debt | 801.71 | 746.28 | 836.95 | 241.27 | 306.35 | Upgrade
|
| Long-Term Leases | 33.67 | 34.82 | 39.94 | 48.02 | 37.07 | Upgrade
|
| Other Long-Term Liabilities | 104.34 | 35.01 | 155.21 | 22.03 | 0.41 | Upgrade
|
| Total Liabilities | 1,001 | 871.06 | 1,090 | 812.18 | 712.82 | Upgrade
|
| Common Stock | 0.1 | 0.09 | 0.07 | 0.04 | 0.04 | Upgrade
|
| Additional Paid-In Capital | 3,197 | 2,885 | 2,375 | 1,931 | 1,720 | Upgrade
|
| Retained Earnings | -3,727 | -3,375 | -2,962 | -2,378 | -1,962 | Upgrade
|
| Comprehensive Income & Other | 28.96 | 1.2 | 0.01 | 0.18 | 0 | Upgrade
|
| Total Common Equity | -500.47 | -489.1 | -586.99 | -447.33 | -242.17 | Upgrade
|
| Minority Interest | 0.9 | 0.97 | 1.05 | -2.49 | -1.74 | Upgrade
|
| Shareholders' Equity | -499.57 | -488.13 | -585.94 | -449.82 | -243.91 | Upgrade
|
| Total Liabilities & Equity | 501.9 | 382.93 | 504.45 | 362.36 | 468.91 | Upgrade
|
| Total Debt | 844.72 | 789.82 | 883.68 | 725.33 | 648.26 | Upgrade
|
| Net Cash (Debt) | -601.9 | -640.01 | -616.32 | -617.31 | -330.32 | Upgrade
|
| Net Cash Per Share | -0.65 | -0.91 | -1.21 | -1.54 | -0.85 | Upgrade
|
| Filing Date Shares Outstanding | 1,028 | 853.44 | 673.95 | 435.84 | 397.91 | Upgrade
|
| Total Common Shares Outstanding | 1,012 | 852.9 | 670.87 | 421.57 | 397.83 | Upgrade
|
| Working Capital | 253.12 | 129.64 | 235.8 | -360.28 | -34.65 | Upgrade
|
| Book Value Per Share | -0.49 | -0.57 | -0.87 | -1.06 | -0.61 | Upgrade
|
| Tangible Book Value | -514.42 | -505.03 | -604.08 | -467.33 | -243.59 | Upgrade
|
| Tangible Book Value Per Share | -0.51 | -0.59 | -0.90 | -1.11 | -0.61 | Upgrade
|
| Machinery | 65.13 | 75.44 | 71.8 | 69.85 | 55.34 | Upgrade
|
| Construction In Progress | 86.43 | 86.42 | 84.44 | 72.69 | 16.58 | Upgrade
|
| Leasehold Improvements | 73.14 | 73.13 | 72.55 | 68.71 | 62.48 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.